Incorporating CSF ctDNA into routine evaluation may improve therapeutic alignment across sanctuary sites; when feasible, maintaining EGFR blockade should be considered when CNS involvement is suspected in EGFR-mutated NSCLC in routine practice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.